Here, we demonstrate that partial genetic ablation of the Dhcr7 gene and pharmacological blockade of DHCR7 activity with the AY9944 inhibitor suppresses hepatic steatosis (↓ lipid area, n = 15; p <0.001), inflammation (↓ F4/80, n = 6; p <0.01), fibrosis (↓ Sirius red, n = 6; p <0.01), and HCC (↓ AFP/YAP, n = 6; p <0.01) in diethylnitrosamine (DEN)-challenged high-fat diet (HFD) + ethanol (EtOH)-fed mice treated with AY9944 compared with control mice. This evidence concerns the gene YAP1 and fatty liver disease.